APA (7th ed.) Citation

Schulze, F., Schaible, J., Goettel, M., Tanaka, Y., Hohl, K., Schultz, A., & Jang, I. (2025). Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers. Naunyn-Schmiedeberg's Archives of Pharmacology, 1-16. https://doi.org/10.1007/s00210-025-03838-0

Chicago Style (17th ed.) Citation

Schulze, Friedrich, Jennifer Schaible, Markus Goettel, Yuko Tanaka, Kathrin Hohl, Armin Schultz, and In-Jin Jang. "Phase 1 Studies of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BI 690517 (vicadrostat), a Novel Aldosterone Synthase Inhibitor, in Healthy Male Volunteers." Naunyn-Schmiedeberg's Archives of Pharmacology 2025: 1-16. https://doi.org/10.1007/s00210-025-03838-0.

MLA (9th ed.) Citation

Schulze, Friedrich, et al. "Phase 1 Studies of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BI 690517 (vicadrostat), a Novel Aldosterone Synthase Inhibitor, in Healthy Male Volunteers." Naunyn-Schmiedeberg's Archives of Pharmacology, 2025, pp. 1-16, https://doi.org/10.1007/s00210-025-03838-0.